[1]
|
R. Dummer, K. Asagoe, A. Cozzio, G. Burg, U. Doebbeling and P. Golling, “Recent Advances in Cutaneous Lymphomas,” Journal of Dermatological Science, Vol. 48, No. 3, 2007, pp. 157-167.
HUdoi:10.1016/j.jdermsci.2007.09.001U
|
[2]
|
C. M. Magro, P. Porcu, J. S. Schaefer, J. W. Erter, R. R. Furman and P. K. Shitabata et al., “Cutaneous CD4+ CD56+ Hematologic Malignancies,” Journal of the American Academy Dermatology, Vol. 63, No. 2, 2010, pp. 292-308. HUdoi:10.1016/j.jaad.2009.08.044U
|
[3]
|
R. G. Asher and K. Hollowood, “Primary Cutaneous Lymphoma: An Overview Based on the WHO-EORTC Classification, Mini-Symposium: Haematopathology Update III,” Diagnostic Histopathology, Vol. 16, No. 4, 2010, pp. 168-181.
|
[4]
|
K. K. Sra, J. W. Labiche, R. Rapini, R. Jordon, S. Raimer and S. Tyring, “T/Natural Killer-Cell Lymphomas,” Journal of the American Academy Dermatology Letters, 2005, pp. 708-709.
|
[5]
|
M. W. Bekkenk, P. M. Jansen, C. J. L. M. Meijer and R. Willemze, “CD56+ Hematological Neoplasms Presenting in the Skin: A Retrospective Analysis of 23 New Cases and 130 Cases from the Literature,” Annals of Oncology, Vol. 15, No. 7, 2004, pp. 1097-1108.
HUdoi:10.1093/annonc/mdh268U
|
[6]
|
Y. L. Kwong, “Natural Killer-Cell Malignancies: Diagnosis and Treatment,” Leukemia, Vol. 19, No. 12, 2005, pp. 2186-2194. HUdoi:10.1038/sj.leu.2403955U
|
[7]
|
M. Shapiro, M. A. Wasik, J. M. Junkins-Hopkins, A. H. Rook, C. C. Vittorio and H. Ikatura et al., “Complete Remission in Advanced Blastic NK-Cell Lymphoma/ Leukemia in Elderly Patients Using the Hyper-CVAD Regimen,” American Journal of Hematology, Vol. 74, No. 1, 2003, pp. 46-51. HUdoi:10.1002/ajh.10381UH
|
[8]
|
J. W. Tjiu and C. H. Hsiao, “Blastic Natural Killer-Cell Lymphoma Presenting in the Skin,” Tzu Chi Medical Journal, Vol. 19, No. 3, 2007, pp. 173-178.
http://health.elsevier.com/tcmj
|
[9]
|
R. P. Falcao, A. B. Garcia, M. G. Marques, B. P. Simoes, B. A. Fonseca and M. L. Rodrigues, et al., “Blastic CD4 NK Cell Leukemia/Lymphoma: A Distinct Clinical Entity,” Leukemia Research, Vol. 26, No. 9, 2002, pp. 803-807.
|
[10]
|
R. Suzuki and S. Nakamura, “Malignancies of Natural Killer (NK) Cell Precursor: Myeloid/NK Cell Precursor Acute Leukemia and Blastic NK Cell Lymphoma/ Leukemia,” Leukemia Research, Vol. 23, No. 7, 1999, pp. 615-624.
|
[11]
|
J. V. E. Reyes, T. Al-Saleem, V. G. Robu and M. R. Smith, “Extranodal NK/T-cell Lymphoma Nasal Type: Efficacy of Pegaspargase. Report of Two Patients from the United States and Review of Literature,” Leukemia Research, Vol. 34, No. 1, 2010, pp. 50-54.
HUdoi:10.1016/j.leukres.2009.09.002U
|
[12]
|
M. Yamaguchi, R. Suzuki, Y. L. Kwong, W. S. Kim, Y. Hasegawa and J. Izutsu Kiya, et al., “Phase I Study of Dexamethasone, Methotrexate, Ifosfamide, L-Asparaginase and Etoposide (SMILE) Chemotherapy for Advanced-Stage, Relapsed or Refractory Extranodal Natural Killer (NK)/T-cell Lymphoma and Leukemia,” Cancer Science, Vol. 99, No. 5, 2008, pp. 1016-1020.
HUdoi:10.1111/j.1349-7006.2008.00768.xU
|
[13]
|
P. Ng Ashley, L. Stephen, R. Timothy, Mc. Cormack, C. Prince and H. M. D. Awesterman, “Primary Cutaneous CD4+/CD56+ Hematodermic Neoplasm (Blastic NK-Cell Lymphoma): A Report of Five Cases,” Hematologica, Vol. 91, No. 1, 2008, pp. 143-144.
http://www.haematologica.org/journal/2006/01/143html
|
[14]
|
J. J. Leitenberger, C. N. Berthelot, K. D. Polder, P. McLaughlin, D. Jones and M. Duvic, “CD4+ CD56+ Hematodermic/Plasmacytoid Dendritic Cell Tumor with Response to Pralatrexate,” Journal of the American Academy Dermatology, Vol. 58, No. 3, 2008, pp. 480-484.
Udoi:10.1016./jaad.2004
|
[15]
|
E. C. Parlette, Z. Elliott, F. W. Hall and B. S. Grabam, “Primary Cutaneous Blastic Natural Killer Cell Lymphoma,” Journal of the American Academy Dermatology, Vol. 53, No. 4, 2005, pp. 742-743.
|